Document Detail


Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
MedLine Citation:
PMID:  8809167     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A variety of compounds having a benzopyran such as levcromakalim generally exhibit potent antihypertensive activity. During extensive investigations aimed toward identifying K+ channel openers having selective coronary vasodilation without potent hypotensive and tachycardiac effects, we synthesized a series of 3,4-dihydro-2H-1-benzopyran-3-ol derivatives modified at positions 2, 4, and 6 in the benzopyran ring. Initially, compounds having two methoxymethyl groups at position 2 were found to show a selective effect on coronary blood flow (CoBF) relative to mean arterial pressure (MAP) in anesthetized dogs. To find more potent vasodilators, various benzopyran derivatives modified at position 4 were synthesized and structure-activity relationships were examined by evaluation of the extent and duration of the increase in CoBF in anesthetized dogs. As a result, compounds having a (1,6-dihydro-6-oxopyridazin-3-yl)amino group at position 4, in addition to the two methoxymethyl groups at position 2, were found to be more potent and to have an improved duration of action. Among these compounds, JTV-506, (-)-(3S,4R)-6-cyano-3,4-dihydro-4-[(1,6-dihydro-1-methyl-6-oxopyridaz in-3-yl)amino]-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol, exhibited good selectivity for its effect. Administration of this compound (0.03 mg/kg, p.o.) elicited an increase of CoBF without a change of systemic blood pressure and heart rate (HR) in conscious dogs. Further evaluation was performed with respect to (i) the selectivity of its action on the coronary artery versus the aorta and (ii) its effects on MAP, HR, and electrocardiographic ST elevation. As a result, JTV-506 was selected as a potent and selective coronary vasodilator with various pharmacological features favoring clinical development.
Authors:
H Cho; S Katoh; S Sayama; K Murakami; H Nakanishi; Y Kajimoto; H Ueno; H Kawasaki; K Aisaka; I Uchida
Related Documents :
2829657 - Esmolol decreases the adverse effects of acute coronary artery occlusion on myocardial ...
7692177 - Acute hemodynamic and neurohumoral profile of dilevalol in hypertensive patients with i...
3489137 - The relationship between coronary pressure during reperfusion and myocardial recovery a...
2437287 - Inhibition of leukotriene d4-induced coronary vasoconstriction by leukotriene antagonis...
9631807 - Delivery of inhaled nitric oxide using the ohmeda inovent delivery system.
4447107 - A longitudinal study of blood pressure in childhood.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of medicinal chemistry     Volume:  39     ISSN:  0022-2623     ISO Abbreviation:  J. Med. Chem.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  1996-11-04     Completed Date:  1996-11-04     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  9716531     Medline TA:  J Med Chem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3797-805     Citation Subset:  IM    
Affiliation:
Japan Tobacco Inc., Central Pharmaceutical Research Institute, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzopyrans / administration & dosage,  chemical synthesis*,  pharmacology
Blood Pressure / drug effects
Coronary Circulation / drug effects
Coronary Vessels / drug effects*,  physiology
Dogs
Female
Heart Rate / drug effects
Ion Channel Gating / drug effects*
Male
Models, Molecular
Molecular Structure
Potassium Channels / physiology*
Pyridazines / administration & dosage,  chemical synthesis*,  pharmacology
Rats
Rats, Sprague-Dawley
Structure-Activity Relationship
Swine
Vasodilator Agents / chemical synthesis*,  pharmacology
Chemical
Reg. No./Substance:
0/6-cyano-3,4-dihydro-4-((1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)amino)-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol; 0/Benzopyrans; 0/Potassium Channels; 0/Pyridazines; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
Next Document:  A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.